To recruit Clinical Laboratory Improvements Program (CLIA) accredited laboratories to participate in ComboMATCH, the National Cancer Institute (NCI) published two solicitations in the Federal Register, effective March 11, 2020. The solicitations were for laboratories that test tumor specimens from patients utilizing next-generation sequencing (NGS) assays:

  • Laboratory sites identifying cases from the general population
  • Laboratory sites identifying exclusively pediatric cases
  • When this trial opens, the recruited laboratories (to be announced) will identify patients who have the specific gene abnormalities needed for trial eligibility using assays they perform as standard-of-care. Laboratories will contact physicians at participating clinical sites if a specimen they send for testing has a gene abnormality that would potentially make the patient eligible for one of the treatment arms.

    ECOG-ACRIN Cancer Research Group